A new report paints a stark picture of how a subset of large healthcare providers is drawing the lion’s share of 340B savings within a single state. The controversial drug discount program has been ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Claims by big hospital systems that the 340B Drug Pricing Program is “doing exactly what Congress intended” (“Comment: Hospitals staying true to Congress’ drug discounts,” The Herald, Feb. 14) ignore ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Minnesota state-covered entities generated at least $1.34 billion in net 340B revenue in calendar year 2024 — more than double the $630 million reported in 2023. A Feb. 27 report to the Legislature ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful. The 340B program ...

A federal judge handed down a decision this week in a lawsuit involving the 340B prescription drug discount program as hospitals, physicians, and drug manufacturers continue to battle over how the ...

Although 340B is a national program, Minnesota was the first state to pass legislation to collect and report data on how it benefits hospitals. The 2024 study tabulated a lower amount of subsidies ...

ADAM JAKUBIK is an economist in the IMF’s Strategy, Policy, and Review Department. ELIZABETH VAN HEUVELEN is a senior economist in the IMF’s Strategy, Policy, and Review Department. Opinions expressed ...